Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$64.95 – $86.20
56% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.78B | $4.56B | $5.44B | $6.72B | $6.71B | $6.51B | $6.95B | $7.29B |
| Cost of revenue | $1.35B | $1.50B | $1.75B | $2.15B | $5.20B | $5.14B | $2.24B | $2.33B |
| Gross profit | $2.43B | $3.06B | $3.69B | $4.57B | $1.51B | $1.37B | $4.71B | $4.97B |
| Gross margin | 64.3% | 67.1% | 67.9% | 68.0% | 22.5% | 21.1% | 67.8% | 68.1% |
| R&D | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | $337.5M | $421.9M | $1.29B | $1.26B | $783.2M | $1.24B | $726.2M | $818.3M |
| EBITDA | $656.8M | $864.9M | $1.27B | $1.54B | $1.35B | $1.22B | $1.37B | $1.53B |
| Net income | $223.9M | $195.2M | $539.4M | $782.6M | $610.2M | $310.2M | $406.4M | $474.8M |
| Net margin | 5.9% | 4.3% | 9.9% | 11.6% | 9.1% | 4.8% | 5.8% | 6.5% |
| EPS (diluted) | 1.22 | 1.05 | 2.75 | 3.90 | 3.07 | 1.57 | 2.09 | 2.54 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $7.4B | $3.67 | $3.55–$3.75 | 1 |
| 2027 | $7.8B | $4.27 | $4.13–$4.38 | 1 |
| 2028 | $8.4B | $4.98 | $4.82–$5.10 | 1 |
| 2029 | $9.2B | $5.34 | $5.16–$5.47 | 1 |
Forward consensus · source: Financial Modeling Prep
EUROFINS SCIENTIFIC SA
No one on the platform currently holds ERFSF.
No tracked institution reports a position in ERFSF as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-04-29 | $0.7200 | 2026-04-30 |
| 2025-04-29 | $0.6000 | 2025-04-30 |
| 2024-07-03 | $0.5000 | 2024-07-05 |
| 2023-07-03 | $1.0000 | 2023-07-06 |
| Execution date | Ratio |
|---|---|
| 2020-11-27 | 10-for-1 |
No one on the platform has traded ERFSF yet.
| -1.08% |
| $5.3B |
| — |
| CHEOYCochlear Limited | $41.98 | +0.57% | $5.5B | — |
| CHJTFCSPC Pharmaceutical Group Limited | $0.98 | +0.00% | $11.2B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 17.1× earnings vs its 27.5× historical median P/E.
Fair value ≈ $123.90 · price $76.93 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.